Merck KGaA looks to big buys after 2014; Some blood pressure meds linked to breast cancer; Endo revenues fall;

@FiercePharma: From FierceVaccines.com: GSK adding 2-D barcode to 4-in-1 flu vaccine packaging. Story  | Follow @FiercePharma

@CarlyHFierce: Bayer says Eylea meets goal in diabetic macular edema trials. Release | Follow @CarlyHFierce

> Merck KGaA is planning ahead and says it expects to spend more time and money on aquisitions from 2014 to 2016. Story

> GlaxoSmithKline ($GSK) has gotten FDA approval to begin shipping its Fluarix quadrivalent, its first four-strain influenza vaccine, for the 2013-14 flu season. Item

> Drugmakers are furious over a move by Australian regulators to cut prices on nearly 500 drugs without their input. Story

> Researchers have found a link between long-term use of calcium-channel blocker blood-pressure meds and breast cancer in women. Story

> Regulators in China have asked a Chinese subsidiary of U.S.-based Abbott Laboratories ($ABT) to recall two infant formula products. Story

> Endo Health Solutions reported that second quarter revenues of $767 million were down 2% from a year ago. Release

> A $65 million milestone payment to Arena Pharma ($ARNA) from partner Eisai for weight-loss drug Belviq allowed the company to report a 213% increase in revenues to $68.9 million in the second quarter from the same time last year. Report

Medical Device News

@FierceMedDev: Freedom Meditech lands $7M for diabetes device. Story | Follow @FierceMedDev

@DamianFierce: Latest in the BRCA battle: Ambry files antitrust suit against Myriad, claiming monopoly. Article | Follow @DamianFierce

@MichaelGFierce: Ocular Therapeutix nets FDA panel meeting for eye surgery hydrogel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Volcano nudges revenue higher in Q2, but swings to a loss. Item

> Life Tech owes Enzo $48.6M after patent fight. Story

Biotech News

@FierceBiotech: Still trending: FDA OKs 5 blockbusters in slow start to 2013 drug approvals. Report | Follow @FierceBiotech

@JohnCFierce: How can you highlight Irish takeover targets and not mention Shire in the lead? Jazz, Alkermes on top. Bloomberg story | Follow @JohnCFierce

@RyanMFierce: Medicines Co. wraps $240M deal to buy ProFibrix following PhIII success. Story | Follow @RyanMFierce

> Novartis grabs lead IL-17 program as Ensemble adds another marquee deal. Report

> Apexigen lands $20M round as China biotech partners advance antibodies. News

> Oncobiologics allies with inVentiv on biosimilars development. Item

Pharma Manufacturing News

@EricPFierce: Thermo Fisher has opened what it says is the first DPM plant in Singapore to tap growing biologics market. Article | Follow @EricPFierce

> Merck New Jersey plant to close in October. Story

> GSK adding 2-D barcodes to vaccine containers. Report

> Sanofi to make API for Vivus ED drug Stendra. Item

> Manufacturers' policies put hurt on execution drug supplies. Article

Biotech Research News

> Opioid receptor research could help shape drug development for addiction. More

> Plant-based inhibitor could halt HIV infection. Item

> NIH team sees diabetes drug as a possible tool for extending life. Story

> New hep C model could pave way for novel treatments. Article

> La Jolla, Kyowa Hakko Kirin partner on autoimmune disease drug discovery. More

And Finally... A new study of 158 years of the Swedish population found that people who are born during whooping cough epidemics and survive are more likely to die prematurely later in life. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.